기본 통계
| LEI | 5299004O0R5XXLA5H544 |
| CIK | 1369568 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Catalyst Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 28, 2026 |
PREM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240. |
|
| May 28, 2026 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 4,091,931,986. |
|
| May 12, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 11, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exa |
|
| May 11, 2026 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., - May 11, 2026 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or |
|
| May 8, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 7, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 6, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2026 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION VOTING AGREEMENT This Voting Agreement (this “Agreement”) is entered into as of August 6, 2026 by and between Angelini Pharma S.p.A., an entity organized under the laws of Italy (“Parent”), and (“Stockholder”). RECITALS A. Stockholder is a holder of record and the “beneficial owner” (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, |
|
| May 7, 2026 |
EX-99.2 Exhibit 99.2 Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. (“Cataly |
|
| May 7, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 6, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) |
|
| May 7, 2026 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: Catalyst Pharmaceuticals, Inc., a Delaware corporation; Angelini Pharma S.p.A., An Italian Società per azioni; and Angelini Cielo Inc., a Delaware corporation Dated as of May 6, 2026 Table of Contents Section 1 THE MERGER 1.1 Merger of Merger Sub into the Company 5 1.2 Effect of the Merger 5 1.3 Closing; Effective Time 5 1.4 |
|
| May 7, 2026 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease • The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a |
|
| May 7, 2026 |
SECOND AMENDMENT TO BY-LAW OF CATALYST PHARMACEUTICALS, INC. ARTICLE VIII EX-3.1 Exhibit 3.1 SECOND AMENDMENT TO BY-LAW OF CATALYST PHARMACEUTICALS, INC. ARTICLE VIII Section 8.1 Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts. Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if such court does not have jurisdiction thereof, another state court |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. ( |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 18, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 18, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Ex |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 25, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| February 25, 2026 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Gr |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 12, 2026 |
EX-99.1 NASDAQ: CPRX Improving the Lives of Patients Living with Rare Diseases January 2026 Exhibit 99.1 Safe Harbor This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospect |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 5, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| November 5, 2025 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 1, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| October 1, 2025 |
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program CORAL GABLES, Fla., October 1, 2025 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced t |
|
| September 8, 2025 |
144 0001763511 XXXXXXXX LIVE 0001369568 CATALYST PHARMACEUTICALS, INC. 001-33057 355 ALHAMBRA CIRCLE SUITE 801 CORAL GABLES FL 33134 (305) 529-2522 Elsbernd Brian Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 30000 609035.49 122391010 09/08/2025 NASDAQ Common 09/08/2025 Options Granted 12/19/2018 Issuer N 30000 09/08/2025 Cash N Brian D. Elsbernd 355 Alhambra |
|
| September 4, 2025 |
144 0001763511 XXXXXXXX LIVE 0001369568 CATALYST PHARMACEUTICALS, INC. 001-33057 355 ALHAMBRA CIRCLE SUITE 801 CORAL GABLES FL 33134 (305) 529-2522 Elsbernd Brian Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 30000 585640.54 122391010 09/04/2025 NASDAQ Common 09/04/2025 Option Granted - 12/19/2018 Issuer N 30000 09/04/2025 Cash N Brian Elsbernd 355 Alhambra Ci |
|
| September 3, 2025 |
144 0001763511 XXXXXXXX LIVE 0001369568 CATALYST PHARMACEUTICALS, INC. 001-33057 355 ALHAMBRA CIRCLE SUITE 801 CORAL GABLES FL 33134 (305) 529-2522 Elsbernd Brian Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 20000 401514.10 122391010 09/03/2025 NASDAQ Common 09/03/2025 Options Granted 12/19/2018 Issuer N 20000 09/03/2025 Cash Y 09/03/2025 /s/ Jennifer Ruchti, |
|
| August 28, 2025 |
EX-99.1 Exhibit 99.1 UPDATED: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., August 26, 2025- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutic |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 25, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of |
|
| August 27, 2025 |
144 0001292636 XXXXXXXX LIVE 0001369568 CATALYST PHARMACEUTICALS, INC. 001-33057 355 ALHAMBRA CIRCLE SUITE 801 CORAL GABLES FL 33134 (305) 529-2522 Tierney David S Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 26000 525087.81 122391010 08/27/2025 NASDAQ Common 08/27/2025 Option Granted - 12/19/2018 Issuer N 26000 08/27/2025 Cash Y 08/27/2025 /s/ Joshua Schmit |
|
| August 25, 2025 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., August 25, 2025- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical compan |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 25, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) • VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMS • Amifampridine may be considered as a supportive care treatment • Guideline inclusion may raise clinical awareness of cancer-as |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exac |
|
| August 6, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENT This Amendment No. 1 to the License and Collaboration Agreement dated 19 June 2023, is executed and delivered as of |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2025 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 To |
|
| August 4, 2025 |
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors EX-99.1 Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors CORAL GABLES, Fla. – Aug. 4, 2025 – Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business developm |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 1, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| June 2, 2025 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career CORAL GABLES, Fla., June 2, 2025 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 20, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 7, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exa |
|
| May 7, 2025 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Tota |
|
| April 14, 2025 |
2024 ANNUAL REPORTUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Ex |
|
| April 11, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 8, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| April 9, 2025 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals CORAL GABLES, Fla., April 8, 2025—Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patien |
|
| February 26, 2025 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE |
|
| February 26, 2025 |
CATALYST PHARMACEUTICALS, INC. INSIDER TRADING POLICY Exhibit 19.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] CATALYST PHARMACEUTICALS, INC. INSIDER TRADING POLICY 1.0 Purpose 1.1 This Insider Trading Policy (“Policy”) summarizes the policies of Catalyst Pharmaceuticals, Inc. (“C |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 26, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Ex |
|
| February 13, 2025 |
EX-99.B 3 e664195ex99-b.htm Exhibit B Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934. |
|
| February 13, 2025 |
Exhibit A Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Catalyst Pharmaceuticals, Inc. |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 17, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 21, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 21, 2025 |
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan Exhibit 99.1 Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan CORAL GABLES, Fla., January 21, 2023—Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-lic |
|
| January 13, 2025 |
Exhibit 99.1 Improving the Lives of Patients with Rare Diseases NASDAQ: CPRX J.P. Morgan Healthcare Conference January 2025 Safe Harbor This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projec |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 8, 2025 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., January 8, 2025- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2025 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| November 15, 2024 |
November 15, 2024 Michael W. Kalb EVP and Chief Financial Officer CATALYST PHARMACEUTICALS, INC. 355 Alhambra Circle Suite 801 Coral Gables, FL 33134 Re: CATALYST PHARMACEUTICALS, INC. Form 10-Q for the period ending June 30, 2024 Filed August 7, 2024 Form 8-K filed February 29, 2024 File No. 001-33057 Dear Michael W. Kalb: We have completed our review of your filings. We remind you that the compa |
|
| November 14, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G/A 1 e664028sc13ga-cp.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Catalyst Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14888U101 (CUSIP Number) Septem |
|
| November 8, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us14888u1016110824.txt us14888u1016110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 6, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| November 6, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational Excellence and Strong Commercial Execution FIRDAPSE® Q3 2024 Ne |
|
| November 6, 2024 |
4r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 4r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2024 |
November 4, 2024 VIA EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 18, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us14888u1016101824.txt us14888u1016101824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| October 17, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 CatalystPharmaInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CATALYST PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 14888U101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 24, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) ( |
|
| September 26, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan CORAL GABLES, Fla., September 24, 2024—Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, tod |
|
| September 17, 2024 |
September 17, 2024 Michael W. Kalb EVP and Chief Financial Officer CATALYST PHARMACEUTICALS, INC. 355 Alhambra Circle Suite 801 Coral Gables, FL 33134 Re: CATALYST PHARMACEUTICALS, INC. Form 10-Q for the period ending June 30, 2024 Filed August 7, 2024 Form 8-K filed February 29, 2024 File No. 001-33057 Dear Michael W. Kalb: We have reviewed your September 5, 2024 response to our comment letter an |
|
| September 5, 2024 |
355 Alhambra Circle, Suite 801 | Coral Gables, FL 33134 | Phone (305) 420-3200 | Fax (305) 569-0233 September 5, 2024 VIA EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| August 16, 2024 |
August 16, 2024 Michael W. Kalb EVP and Chief Financial Officer CATALYST PHARMACEUTICALS, INC. 355 Alhambra Circle Suite 801 Coral Gables, FL 33134 Re: CATALYST PHARMACEUTICALS, INC. Form 10-Q for the period ending June 30, 2024 Filed August 7, 2024 Form 8-K filed February 29, 2024 File No. 001-33057 Dear Michael W. Kalb: We have limited our review of your filings to the financial statements and r |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 7, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exac |
|
| August 7, 2024 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] LICENSE, SUPPLY AND COMMERCIALIZATION AGREEMENT This License, Supply and Commercialization Agreement, is made as of July 23, 2024 (the “Effective Date”), by and between C |
|
| August 7, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million, Representing a 23.2% YoY Increase FIRDAPSE® Q2 2024 Net Product Revenues of $77.4 Mill |
|
| July 26, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada CORAL GABLES, Fla., July 24, 2024 — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients l |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 24, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| May 31, 2024 |
Power of Attorney (included in the signature page hereto) As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Exhibit 107 Form S-8 (Form Type) Catalyst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Power of Attorney (included in the signature page hereto) As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Power of Attorney (included in the signature page hereto) As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 30, 2024 |
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® CORAL GABLES, Fla., May 30, 2024 — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat d |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 21, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exa |
|
| May 8, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE® Successfully |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 8, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commiss |
|
| April 10, 2024 |
2023 ANNUAL REPORTUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Ex |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 13, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for Patients Aged Two Years and Older Catalyst Pathways® Pro |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 13, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 28, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| February 29, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Pe |
|
| February 28, 2024 |
EX-97.1 Exhibit 97.1 CATALYST PHARMACEUTICALS, INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Catalyst Pharmaceuticals, Inc., a Delaware corporation (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performanc |
|
| February 28, 2024 |
Offer Letter between the Company and Michael W. Kalb* Exhibit 10.1(b) Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. December 1, 2023 Michael W. Kalb [***] Dear Mike, We are pleased to extend you an offer of employment with Catalyst Pharmaceuticals, Inc., (“C |
|
| February 28, 2024 |
Offer Letter between the Company and Richard J. Daly EX-10.1(a) Exhibit 10.1(a) Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. October 18, 2023 Richard J. Daly [***] Dear Rich, We are pleased to extend you an offer of employment with Catalyst Pharmaceuticals |
|
| February 28, 2024 |
Separation Agreement between the Company and Alicia Grande Exhibit 10.1(d) Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is entered into between Catalyst Pharmace |
|
| February 28, 2024 |
Severance and Change in Control Plan Exhibit 10.4 CATALYST PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE AND CHANGE IN CONTROL PLAN EFFECTIVE: FEBRUARY 22, 2018 AMENDED: MAY 24, 2018 FURTHER AMENDED: NOVEMBER 16, 2023 The purpose of this Executive Severance and Change in Control Plan (the “Plan”) of Catalyst Pharmaceuticals, Inc. (the “Company”) is to provide designated senior management employees of the Company with certain compensation |
|
| February 28, 2024 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2024 |
Separation Agreement between the Company and Patrick J. McEnany* Exhibit 10.1(c) Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is entered into between Catalyst Pharmace |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 21, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| February 21, 2024 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology Santhera’s Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of Vamorolone CORA |
|
| February 13, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0553-catalystpharmaceutica.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Catalyst Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 14888U101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| February 12, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619253sc13ga-cp.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Catalyst Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14888U101 (CUSIP Number) Decemb |
|
| January 25, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING CATALYST PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 14888U101 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHED |
|
| January 22, 2024 |
CPRX / Catalyst Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us14888u1016012224.txt us14888u1016012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 9, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| January 9, 2024 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock CORAL GABLES, Fla., January 9, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares of its co |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| January 8, 2024 |
NASDAQ: CPRX Dedicated to Making a Meaningful Difference in the Lives of Patients Suffering from Rare and Difficult to Treat Diseases January 2024 Exhibit 99. |
|
| January 5, 2024 |
Subject to Completion, Preliminary Prospectus Supplement, dated January 4, 2024 Form 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 4, 2024 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| January 5, 2024 |
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock CORAL GABLES, FL, January 4, 2024 — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up |
|
| January 5, 2024 |
Exhibit 1.1 CATALYST PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 4, 2024 CATALYST PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT BofA Securities, Inc. Citigroup Global Markets Inc. as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Par |
|
| January 5, 2024 |
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock EX-99.2 Exhibit 99.2 Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock CORAL GABLES, FL, January 5, 2024 — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $15 |
|
| January 5, 2024 |
10,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333- 274427 PROSPECTUS SUPPLEMENT (To Prospectus dated September 8, 2023) 10,000,000 Shares Common Stock We are offering 10,000,000 shares of our common stock. Our shares trade on the Nasdaq Capital Market under the symbol CPRX. On January 4, 2024, the last reported sale price of our common stock as reported on the Nasdaq Capital |
|
| December 19, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma CORAL GABLES, Fla., Dec 18, 2023—Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its col |
|
| December 19, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 18, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| December 8, 2023 |
EX-FILING FEES Exhibit 107 Form S-8 (Form Type) Catalyst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Ca |
|
| December 8, 2023 |
As filed with the Securities and Exchange Commission on December 8, 2023 S-8 As filed with the Securities and Exchange Commission on December 8, 2023 Registration No. |
|
| December 8, 2023 |
As filed with the Securities and Exchange Commission on December 8, 2023 S-8 As filed with the Securities and Exchange Commission on December 8, 2023 Registration No. |
|
| December 8, 2023 |
EX-FILING FEES Exhibit 107 Form S-8 (Form Type) Catalyst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Ca |
|
| December 7, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions Ms. Alicia Grande, Catalyst’s Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CO |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 1, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License Third Quarter 2023 Non-GAAP Net Inc |
|
| November 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. |
|
| November 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 8, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 2, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| November 3, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE® New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio CORAL GABLES, Fla., November 2, 2023 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing nove |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 26, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| October 27, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential |
|
| October 20, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalyst’s Chairman CORAL GABLES, Fla., Oct. 19, 2023 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicin |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 18, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 13, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| October 13, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE® The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL GABLES, Fla., October 13, 2023 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Compan |
|
| September 26, 2023 |
NASDAQ: CPRX Dedicated to Making a Meaningful Difference in the Lives of Patients Suffering from Rare and Difficult to Treat Diseases September 2023 Exhibit 99. |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 26, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) ( |
|
| September 8, 2023 |
EX-FILING FEES Exhibit 107 Form S-3 (Form Type) Catalyst Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Ca |
|
| September 8, 2023 |
As filed with the Securities and Exchange Commission on September 8, 2023 Form S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 8, 2023 Registration No. |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 22, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter Non-GAAP |
|
| August 9, 2023 |
EX-10.1 EXHIBIT 10.1 Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. AMENDMENT TO TRANSITION SERVICES AGREEMENT This Amendment to Transition Services Agreement (this “Amendment”), dated as of July 31, 2023 |
|
| August 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 9, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exac |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 24, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| July 28, 2023 |
EX-99.1 Exhibit 99.1 Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End Mr. McEnany will Continue to Serve as Catalyst’s Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Comp |
|
| July 21, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst’s Expertise and Bolsters Catalyst’s Rare Neuroscience Portfolio Granted |
|
| July 21, 2023 |
Amendment to the Investment Agreement, dated as of July 18, 2023, between Santhera and the Company EX-10.3 Exhibit 10.3 Amendment to the Investment Agreement dated as of July 18, 2023 between Santhera Pharmaceuticals Holding AG Hohenrainstrasse 24 4133 Pratteln Switzerland (the Company) and Catalyst Pharmaceuticals, Inc. 355 Alhambra Circle Suite 801 Coral Gables, Florida 33134 USA (the Investor) (each the Company and the Investor a Party and together the Parties) Amendment to the Investment Ag |
|
| July 21, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 18, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| July 17, 2023 |
FORM ARS ANNUAL REPORT TO SHAREHOLDERS FOR 12-31-2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of regist |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 23, 2023 |
Investment Agreement, dated as of June 19, 2023, by and between Santhera and the Company EX-10.2 EXHIBIT 10.2 Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. Investment Agreement dated as of June 19, 2023 by and between Santhera Pharmaceuticals Holding AG Hohenrainstrasse 24 4133 Pratteln Switz |
|
| June 23, 2023 |
EX-10.1 EXHIBIT 10.1 Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. LICENSE AND COLLABORATION AGREEMENT This Cooperation, Supply and Commercialization Agreement, executed and delivered as of June 19, 2023 |
|
| June 23, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals June 20, 2023 at 6:00 AM EDT Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 19, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| June 1, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023 Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an Increase of 17% YoY Forecasts FYCOMPA® 2023 Net Product Revenue of Approximately $130 Million for 11 Months Reaffirms |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 25, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 30, 2023 |
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors CORAL GABLES, Fla., May 30, 2023 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year • Reports Record Total Revenues of $85.4 Million for Q1 2023 • Delivers Revenue Growth of 98%, a Record Increase YoY • GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY • Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY • Affirms Full Yea |
|
| May 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exa |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 Coral Gables, Fla., May 9, 2023 — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stag |
|
| April 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCH A NGE COMMISSION Washington, D. |
|
| April 10, 2023 |
CATALYST PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.2 Exhibit 99.2 CATALYST PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Eisai Co., Ltd. (“Eisai”). Pursuant to the terms of the Purchase Agreement, on January 24, 2023, the Company acquired Eisai’s U.S. rights, title |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 24, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction o |
|
| April 10, 2023 |
FYCOMPA® PRODUCT LINE OF EISAI CO., LTD. AND SUBSIDIARIES Abbreviated Financial Statements EX-99.1 Exhibit 99.1 FYCOMPA® PRODUCT LINE OF EISAI CO., LTD. AND SUBSIDIARIES Abbreviated Financial Statements Table of Contents INDEPENDENT AUDITOR’S REPORT 2 ABBREVIATED FINANCIAL STATEMENTS: Statement of Assets Acquired and Liabilities Assumed for the periods ended March 31, 2022 and December 31, 2022 3 Statement of Revenues and Direct Expenses for the periods ended March 31, 2022 and December |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 29, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 15, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| March 15, 2023 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of |
|
| March 15, 2023 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 1, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2023 |
CPRX / Catalyst Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-cprx123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CATALYST PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 14888U101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| February 10, 2023 |
CPRX / Catalyst Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 9, 2023 |
CPRX / Catalyst Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Catalyst Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 14888U101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| February 8, 2023 |
CPRX / Catalyst Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMEMDED FILING CATALYST PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 14888U101 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHED |
|
| February 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 7, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| February 7, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance 2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA®, Representing YoY Growth of 75%—80% 2023 FIRDAPSE® Net Revenues Estimated at $245 Mi |
|
| January 30, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 24, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 30, 2023 |
Exhibit 99.1 Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 CORAL GABLES, Fla., Jan. 25, 2023 — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial |
|
| January 26, 2023 |
CPRX / Catalyst Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us14888u1016012623.txt us14888u1016012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| January 24, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 23, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 24, 2023 |
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE® Exhibit 99.1 Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE® CORAL GABLES, Fla., Jan. 23, 2023 — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical co |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 18, 2023 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 23, 2023 |
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE® EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE® CORAL GABLES, Fla., January 23, 2023 – Catalyst Pharmaceuticals, Inc. (“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has rec |
|
| January 20, 2023 |
CPRX / Catalyst Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us14888u1016011923.txt us14888u1016011923.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| December 22, 2022 |
EXHIBIT 99.1 Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA? (Perampanel) CIII From Eisai Co., Ltd Acquisition Expands The Company?s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development Strategy Into Synergistic Adjacencies Transaction Includes Exclusive Period To Eva |
|
| December 22, 2022 |
Exhibit 2.1 Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. ASSET PURCHASE AGREEMENT by and between EISAI CO., LTD. and CATALYST PHARMACEUTICALS, INC. Dated as of December 17, 2022 TABLE OF CONTENTS ARTICLE |
|
| December 22, 2022 |
EXHIBIT 10.1 Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. EXHIBIT J FORM OF TRANSITION SERVICES AGREEMENT TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and Catalyst Pharmaceuticals, Inc. Dated |
|
| December 22, 2022 |
EXHIBIT 10.2 Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted. Exhibit H Form of Supply Agreement SUPPLY AGREEMENT between EISAI CO., LTD. and CATALYST PHARMACEUTICALS, INC. Dated as of [ ? ], 2022 TABLE OF C |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 17, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2022 |
CPRX / Catalyst Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. |
|
| November 9, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update Achieved Record Q3 2022 FIRDAPSE? Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ($0.22 per basic and $0.20 per diluted share), which Includes a One Time Cha |
|
| November 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| October 7, 2022 |
CPRX / Catalyst Pharmaceuticals Inc / BlackRock Inc. Passive Investment us14888u1016100622.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) September 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| September 29, 2022 |
FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. Exhibit 99.1 Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE? Expanding Patient Population to Include Pediatric Patients FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) ? Catalyst Pharmaceuticals, Inc. (?Catalyst?) (Nasdaq: CPRX), a commercial-stage bi |
|
| September 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 29, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) ( |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 19, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) ( |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 8, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (C |
|
| September 9, 2022 |
Exhibit 10.1 EXECUTION VERSION EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT This EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT (?Amendment?) is entered into as of this 8th day of September, 2022, by and between CATALYST PHARMACEUTICALS, INC., a Delaware corporation (?Company?) and PATRICK J. MCENANY (?Employee?). Preliminary Statements A. The parties have previously entered into that certain Employment Agr |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exac |
|
| August 9, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE? Revenues and Provides Corporate Update Achieved Record Q2 2022 FIRDAPSE? Net Product Revenues of $53.0 Million, a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt Completed Acquisition of Ruzurgi? U.S. and Mexico Commercial Ri |
|
| August 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| July 12, 2022 |
EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical As Part of the Settlement, Catalyst has Acquired Certain of Jacobus’ Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® CORAL GABLES, Fla., July 12, 2022 — Catalyst Pharmaceuticals, Inc. (“Cat |
|
| July 12, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION INDICATED BY ?[***]? HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SETTLEMENT AGREEMENT This Settlement Agreement (including Exhibit A) (this ?Agreement? or ?Settlement Agreement?) is made and entered into this 11th day of July, 2022 (the ?Executio |
|
| July 12, 2022 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION INDICATED BY ?[***]? HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AND ASSET PURCHASE AGREEMENT THIS LICENSE AND ASSET PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of July 11, 2022 (the ?Execution Date?), by and between |
|
| July 12, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 11, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE? Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in Innovative Rare Disease Oppor |
|
| May 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 10, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exa |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [Mark One] ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of regi |
|
| March 16, 2022 |
Description of the Company’s Capital Stock Exhibit 4.5 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The common stock, par value $0.001 per share (?Common Stock?), of Catalyst Pharmaceuticals, Inc. (?Catalyst,? ?we,? or ?our?) is registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description sets forth certain genera |
|
| March 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 16, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| March 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Ex |
|
| March 16, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE? Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034 Actively Pursuing Opportunities to Diver |
|
| March 11, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi? CORAL GABLES, Fla., March 11, 2022? Catalyst Pharmaceuticals, Inc. (?Catalyst?) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines f |
|
| March 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 11, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Comm |
|
| March 2, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Further Strengthens FIRDAPSE? U.S. Patent Portfolio Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides Intellectual Property Protection Until 2034 CORAL GABLES, Fla., March 02, 2022 (GLOBE NEWSWIRE) |
|
| March 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 2, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Commi |
|
| February 15, 2022 |
CPRX / Catalyst Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.001 per share, of Catalyst Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 9, 2022 |
CPRX / Catalyst Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Catalyst Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 14888U101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 9, 2022 |
CPRX / Catalyst Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING CATALYST PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 14888U101 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE |
|
| February 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 7, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| February 7, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update 2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million, Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U |
|
| February 3, 2022 |
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi Exhibit 99.1 Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi? is No Longer Valid Earlier this Week the District Court Granted Summary Judgement to Catalyst in Its Lawsuit Against the FDA and this FDA Action is the Result of that Decision CORAL GABLES, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) ? Catalyst Pharmaceuticals, Inc. (?Catalyst?) (Nasdaq: CPRX), a |
|
| February 3, 2022 |
CPRX / Catalyst Pharmaceuticals Inc / BlackRock Inc. Passive Investment us14888u1016020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) CATALYST PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14888U101 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 3, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 28, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| January 28, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst?s Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) ? Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceuti |
|
| January 10, 2022 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.?s Petition for Rehearing CORAL GABLES, Fla., January 10, 2022 ? Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for pa |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| December 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 6, 2021 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
|
| December 6, 2021 |
Exhibit 99.1 Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE? (amifampridine) in Japan CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) ? Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 3, 2021 CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 001-33057 76-0837053 (State or other jurisdiction of incorporation) (Co |
